Uncategorized

Boringly Consistent

It’s ironic on the day that Dexcom reports second quarter results word comes that yet another Dexcom wannabe secured more financing. Will this Belgian wannabe end up coming to market or will it more likely become just another waffle is anyone’s guess. It really doesn’t matter as when it comes to the CGM market it’s owned by two companies and two companies alone, Abbott and Dexcom. Let’s get the numbers out...

Take me out to the ballgame

There is just something special about opening day. There may not be fans in the stands, the crowd noise isn’t real, but baseball is still baseball and in this crazy COVID world we now live in it’s great to have baseball back. How long this will last no one knows but as long as it lasts let’s enjoy it even though fun at the old ballpark will be restricted to...

Random Friday Thoughts

Have you ever noticed that when things don’t go as exactly as planned that people just love to change the narrative. We thought of this today after reflecting on the Abbott earnings call. As we noted yesterday the company went to great lengths extolling just how great the Libre2 is and how it is the most accurate CGM on the planet. Which when you think about this it really makes...

Tap Dancing

Before we get into the analysis of the Abbott call this morning let’s get the numbers out of the way; per the earnings release; “In Diabetes Care, strong growth was led by FreeStyle Libre, which grew 36.8 percent on a reported basis and 39.9 percent on an organic basis versus the prior year. In June, Abbott announced U.S. FDA approval of FreeStyle Libre 2 as an integrated continuous glucose monitoring (iCGM)...

Yep FREE is better

File this under the category of we just can’t make this stuff up. It seems that stock guru Jim Cramer believes that Livongo doesn’t have any competition. According to a post on The Street web site; “According to Jim Cramer's most recent Real Money column, Livongo has "come of age during the pandemic. We have had them on several times and they just pre-announced better than expected earnings last week. Why?...

Boys will be boys

Thursday morning when Abbott reports second quarter results we suspect a big topic of discussion will be the recent approval of the Libre2. As everyone knows by now the approval came with the iCGM designation but also came with the following warning; “The System must not be used with automated insulin dosing (AID) systems, including closed loop and insulin suspend systems. Remove the sensor before MRI, CT scan, X-ray, or diathermy...

Pigs are not just flying they are doing summersaults

We hope everyone is sitting down for this one, per a just issued press release; “Medtronic plc (NYSE:MDT) and Tandem Diabetes Care, Inc. (NASDAQ:TNDM) today announced that they have entered into a non-exclusive patent cross-license agreement for certain technologies in the field of diabetes. Cross-licensing each other’s patent portfolios enables both companies to focus on helping people with diabetes through innovation of future products and services, while avoiding the distraction of...

Free is still better

We’re not sure who said it but there’s an old saying why pay for the cow when you can drink the milk for free. This saying wasn’t directed at our wacky world but when it comes to all the way cool whiz bang apps/coaching platforms free is better. We thought of this today when we learned that Roche has teamed up with the Boots pharmacy chain promoting free access to...

Don’t fight a trend

One thing Momma Kliff taught her boys was never to fight a trend. Although we don’t get it here is the latest from our friends at Livongo who announced preliminary second quarter results this morning. “Livongo now expects revenue for the second quarter of 2020 to be in the range of $86 million to $87 million, up from prior guidance of $73 million to $75 million. The updated revenue outlook includes...

A Deeper Dive

As we prepare for the 4th of July holiday a few thoughts on all the wackiness that has been going on recently in the diabetes toy sector. First comes the FDA approval of the Libre2 with an iCGM designation. Next Abbott and Tandem finalize their agreement to find ways for the Libre to work with Tandem systems. And the biggie Tandem receives coverage from UnitedHealthcare after Medtronic announces their exclusive...